Cronos Group Inc (CRON)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
CRON
Cronos Group Inc
$2.74
-2.14%
HEALTHCARE · Cap: $1.05B
TAK
Takeda Pharmaceutical Co Ltd ADR
$15.60
+0.97%
HEALTHCARE · Cap: $49.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 2824183% more annual revenue ($4.51T vs $159.53M). TAK leads profitability with a 4.3% profit margin vs -1.1%. TAK earns a higher WallStSmart Score of 57/100 (C).
CRON
Hold45
out of 100
Grade: D+
TAK
Buy57
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 40.1% year-over-year
Earnings expanding 126.8% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 330.2% YoY
Areas to Watch
Smaller company, higher risk/reward
ROE of -0.2% — below average capital efficiency
Currently unprofitable
Operating margin of -1.1%
3.9% revenue growth
ROE of 2.5% — below average capital efficiency
4.3% margin — thin
Operating margin of 3.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : CRON
The strongest argument for CRON centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 40.1% demonstrates continued momentum.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.40 suggests the stock is reasonably priced for its growth.
Bear Case : CRON
The primary concerns for CRON are Market Cap, Return on Equity, Profit Margin.
Bear Case : TAK
The primary concerns for TAK are Revenue Growth, Return on Equity, Profit Margin. A P/E of 42.5x leaves little room for execution misses. Thin 4.3% margins leave little buffer for downturns.
Key Dynamics to Monitor
CRON profiles as a hypergrowth stock while TAK is a value play — different risk/reward profiles.
CRON carries more volatility with a beta of 1.25 — expect wider price swings.
CRON is growing revenue faster at 40.1% — sustainability is the question.
CRON generates stronger free cash flow (9M), providing more financial flexibility.
Bottom Line
TAK scores higher overall (57/100 vs 45/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cronos Group Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Cronos Group Inc. is a cannabinoid company. The company is headquartered in Toronto, Canada.
Visit Website →Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?